A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects

NCT ID: NCT04372407

Last Updated: 2021-02-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-09
• Study Completion Date: 2021-01-19

Brief Summary

This study will be a 2-period study conducted with 14 healthy male or female subjects. Subjects will be administered surufatinib alone in Period 1 and in combination with itraconazole in Period 2.

Detailed Description

This study will be a single center, open label, fixed-sequence crossover, 2-period study conducted with 14 healthy male or female subjects. Subjects will be administered surufatinib alone in Period 1 and in combination with itraconazole in Period 2. PK samples will be collected through out both study periods.Subjects will be confined in the clinic from check-in on Day -1 through the end-of study visit on Day 15.

Conditions

Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Treatment Crossover Arm

All patients will receive a single dose of surufatinib on day 1 in period 1, and a both itraconazole and single dose of surufatinib in period 2

Group Type: EXPERIMENTAL

Surufatinib

Intervention Type: DRUG

Surufatinib: 200 mg as single dose on Days 1 and 9

Itraconazole

Intervention Type: DRUG

Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14

Interventions

Surufatinib

Surufatinib: 200 mg as single dose on Days 1 and 9

Intervention Type: DRUG

Itraconazole

Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Non-smoking, healthy male or female between the ages of 18 and 55 years old (inclusive).
• Body mass index (BMI) > 18 and ≤ 29 kg/m2.
• Females must be of non-childbearing potential, or of childbearing potential and agree to use a medically acceptable method of contraception.
• Males who have not had a successful vasectomy and are partners of women of childbearing potential must use, or their partners must use, a highly effective method of contraception starting for at least one menstrual cycle prior to and throughout the entire study period, and for 2 weeks after the last dose of study drug. Those with partners using hormonal contraceptives must also use an additional approved method of contraception. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation.

Exclusion Criteria

• Evidence of clinically significant cardiovascular, hepatic, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities or had a known history of any GI surgery or cholecystectomy.
• Clinically significant illness within 8 weeks or had a clinically significant infection within 4 weeks prior to the first dose.
• Clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations.
• Systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.
• The subject has a clinically significant ECG abnormality, or had a family history of prolonged QTc syndrome or sudden death.
• A history of smoking or use of nicotine-containing substances within the previous 2 months.
• A history of drug or alcohol misuse in the previous 6 months.
• Has been diagnosed with acquired immune deficiency syndrome (AIDS) or are positive for human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
• Has participated in a clinical trial of other drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the subject is currently enrolled in another clinical trial.
• Has received blood or blood products within 4 weeks, or donated blood or blood products within 8 weeks.
• Has used any over-the-counter (OTC) medications or prescription drugs within 2 weeks.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Hutchison Medipharma Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Covance Clinical Research Unit

Dallas, Texas, United States

Countries

United States

Other Identifiers

2019-012-00US2

Identifier Type: -

Identifier Source: org_study_id